UNSPSC 51162107: Isoniazid/rifapentine

Definition: This classification is for a combination medication for TB treatment. The first component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The second component, RIFAPENTINE, has US FDA Unique Ingredient Identifier of XJM390A33U. RIFAPENTINE is an International Non-Proprietary Name or INN.

UNSPSC 51162107 Isoniazid/rifapentine, a Commodity code, represents a narrow pharmaceutical product class with minimal recent state and local solicitation activity. The code nominally covers a specific tuberculosis treatment combination, but the recent opportunities block shows no procurement directly targeting this drug product. Instead, the tagged opportunities span unrelated categories—naloxone procurement, EMS pharmaceuticals and vending systems, forensic drug standards, generic multi-source pharmaceuticals through a cooperative purchasing vehicle, and clinic wellness services—none of which involve isoniazid/rifapentine procurement. The source material contains no recent RFP, RFQ, IFB, or ITQ notices from state agencies, counties, cities, school districts, or transit authorities seeking this specific pharmaceutical, nor does it identify issuing bodies with repeat activity under this code or geographic concentrations of demand.

Given the absence of any recent state or local solicitation activity explicitly tied to isoniazid/rifapentine procurement, this code shows no actionable market signal at this time. Business development professionals should monitor tuberculosis treatment protocols and public health department procurement channels, particularly state health departments and large urban health systems, but no immediate pursuit opportunity is present in the current market data.